Chair

Larry Lynd

University of British Columbia

Opportunity costs of funding genomic technologies

Doug Coyle

Professor, Epidemiology, Public Health and Preventive Medicine, University of Ottawa

The challenges of integrating health economics evidence into policy in the area of genomics: A UK perspective

Katherine Payne

Professor of Health Economics, Manchester Centre for Health Economics, The University of Manchester

Preferences of directly affected participants and the general public for genetic testing and screening: Results from choice experiments

Carlo Marra

Dean and Professor, Pharmacy, Memorial University of Newfoundland

Headroom and value in biotherapeutics R&D

Tania Bubela

Associate Professor and Associate Dean (Research), University of Alberta

New developments in genomic technologies result in increased pressures on private and public payers to pay for more treatments and testing within a constrained budget. Evidence of the cost effectiveness of these new technologies is required, including consideration of downstream costs; however, these evaluations raise questions regarding reimbursement of companion tests for pharmaceuticals, the societal value/willingness to pay for new genomic technologies, and the value of population-based screening. Therefore, this session will explore the nuances of health technology assessment and economic evaluation of new genomic technologies and personalized medicine, including the incorporation of societal values into decisions about funding, reimbursement, and priority-setting.